Cancer Drug Trials Put On Hold After Patients Died
Portfolio Pulse from Bibhu Pattnaik
Clinical trials for cancer treatments conducted by 2seventy bio (NASDAQ:TSVT) and Mersana (NASDAQ:MRSN) have been halted after the deaths of six participants. TSVT's trial focused on acute myeloid leukemia, while MRSN's trial targeted ovarian cancer.
June 17, 2023 | 8:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mersana's phase three clinical trial for ovarian cancer treatment was put on partial hold after five patient deaths, potentially affecting the drug's approval timeline.
The partial hold on Mersana's clinical trial due to multiple patient deaths may result in delays in the drug's development and approval process, negatively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
2seventy bio's clinical trial for acute myeloid leukemia treatment was halted after a patient death, potentially delaying the drug's development.
The halt in 2seventy bio's clinical trial due to a patient death may cause delays in the drug's development and approval process, negatively impacting the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100